EMA Authorised: Ituxredi (rituximab) — Reddy Holding GmbH

View source ↗

Summary

The EMA authorised Ituxredi (rituximab) by Reddy Holding GmbH. It is indicated for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma
• Rheumatoid Arthritis

Drugs mentioned

• Ituxredi (rituximab)

Snippet

Status: Authorised. Therapeutic area: Lymphoma, Non-Hodgkin;Leukemia, Lymphocytic, Chronic, B-Cell;Arthritis, Rheumatoid. MAH: Reddy Holding GmbH. Decision date: 09/07/2025